[go: up one dir, main page]

WO2008060540A3 - Procédés d'identification de compositions qui modulent la protéine tyrosine kinase, ptp-bl - Google Patents

Procédés d'identification de compositions qui modulent la protéine tyrosine kinase, ptp-bl Download PDF

Info

Publication number
WO2008060540A3
WO2008060540A3 PCT/US2007/023845 US2007023845W WO2008060540A3 WO 2008060540 A3 WO2008060540 A3 WO 2008060540A3 US 2007023845 W US2007023845 W US 2007023845W WO 2008060540 A3 WO2008060540 A3 WO 2008060540A3
Authority
WO
WIPO (PCT)
Prior art keywords
ptp
methods
tyrosine phosphatase
modulate
protein tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/023845
Other languages
English (en)
Other versions
WO2008060540A2 (fr
Inventor
Michael J Grusby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008060540A2 publication Critical patent/WO2008060540A2/fr
Publication of WO2008060540A3 publication Critical patent/WO2008060540A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne, au moins partiellement, la découverte que la tyrosine phosphatase, du type PTP-Basophile (PTP-BL), interagit physiquement avec de multiples protéines STAT, par exemple, STAT4, STAT1 et/ou STAT6. L'invention concerne également, au moins partiellement, la génération d'animaux non humains déficients en Ptp-bt1-. En conséquence, l'invention met en oeuvre des procédés pour identifier des modulateurs de l'interaction des polypeptides STAT et des polypeptides PTP-BL ainsi que des animaux non humains déficients en Ptp-bt1- et des cellules dérivés de ces polypeptides et leurs procédés d'utilisation.
PCT/US2007/023845 2006-11-13 2007-11-13 Procédés d'identification de compositions qui modulent la protéine tyrosine kinase, ptp-bl Ceased WO2008060540A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85861506P 2006-11-13 2006-11-13
US60/858,615 2006-11-13
US90049307P 2007-02-09 2007-02-09
US60/900,493 2007-02-09
US90122707P 2007-02-13 2007-02-13
US60/901,227 2007-02-13

Publications (2)

Publication Number Publication Date
WO2008060540A2 WO2008060540A2 (fr) 2008-05-22
WO2008060540A3 true WO2008060540A3 (fr) 2008-10-16

Family

ID=39313222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023845 Ceased WO2008060540A2 (fr) 2006-11-13 2007-11-13 Procédés d'identification de compositions qui modulent la protéine tyrosine kinase, ptp-bl

Country Status (1)

Country Link
WO (1) WO2008060540A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042489A1 (fr) * 2000-11-27 2002-05-30 The Hospital For Sick Children Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t
WO2002096412A1 (fr) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Inhibiteurs de ptpase et leur methode d'utilisation
US20040033979A1 (en) * 1999-04-12 2004-02-19 Dean Nicholas M. Antisense modulation of Fas mediated signaling
US20040224337A1 (en) * 2003-03-04 2004-11-11 Erik Foehr Use of biomolecular targets in the treatment and visualization of tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033979A1 (en) * 1999-04-12 2004-02-19 Dean Nicholas M. Antisense modulation of Fas mediated signaling
WO2002042489A1 (fr) * 2000-11-27 2002-05-30 The Hospital For Sick Children Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t
WO2002096412A1 (fr) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Inhibiteurs de ptpase et leur methode d'utilisation
US20040224337A1 (en) * 2003-03-04 2004-11-11 Erik Foehr Use of biomolecular targets in the treatment and visualization of tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAQUE S J ET AL: "Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 27 OCT 1995, vol. 270, no. 43, 27 October 1995 (1995-10-27), pages 25709 - 25714, XP002489749, ISSN: 0021-9258 *
NAKAHIRA MASAKIYO ET AL: "Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL", IMMUNITY, vol. 26, no. 2, February 2007 (2007-02-01), pages 163 - 176, XP002489752, ISSN: 1074-7613 *
SATO ET AL: "Nuclear retention of STAT3 through the coiled-coil domain regulates its activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 336, no. 2, 21 October 2005 (2005-10-21), pages 617 - 624, XP005165755, ISSN: 0006-291X *
WURSTER ANDREA L ET AL: "Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis.", MOLECULAR AND CELLULAR BIOLOGY JAN 2002, vol. 22, no. 1, January 2002 (2002-01-01), pages 117 - 126, XP002489750, ISSN: 0270-7306 *
ZHU WEI ET AL: "Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 27 SEP 2002, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 35787 - 35790, XP002489751, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008060540A2 (fr) 2008-05-22

Similar Documents

Publication Publication Date Title
MX354100B (es) Formulaciones de proteinas y metodos para elaborarlas.
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2007143204A3 (fr) Compositions et procédés pour modifier des glycans de surface cellulaire
WO2006055689A3 (fr) Squelettes proteiques et leurs utilisations
NO20065084L (no) Interferon-alfa polypeptider og konjugater
BRPI0709598A8 (pt) composições de polipeptídeos estabilizados
WO2011013133A3 (fr) Nouvelles compositions biopesticides et leur procédé d'isolement et de caractérisation
BRPI0412328A (pt) aditivo de alimentos que compreende variantes exomilase não maltogênicas de pseudomonas
EP3252079B8 (fr) Anticorps se liant à la protéine tyrosine phosphatase béta humaine (hptp-beta) et leurs utilisations
WO2004063362A3 (fr) Proteines de la progression du cycle cellulaire
WO2005032487A3 (fr) Enzyme de conversion de l'angiotensine 2 comme recepteur du coronavirus sras
WO2004020458A3 (fr) Tests et compositions d'identification d'agents modulant l'activite d'agents de desubiquitination
WO2008086035A3 (fr) Rapporteur de fusion d'hydrolase mutante divisée et utilisations de celui-ci
WO2007123742A3 (fr) Méthodes et compositions améliorant la fidélité d'assemblage de plusieurs acides nucléiques
WO2009102367A3 (fr) Modulateurs de protéines des jonctions serrées et leurs utilisations
EA200970112A1 (ru) Документ, снабженный идентифицирующими и верификационными данными
WO2007028110A3 (fr) Methodes d'utilisation et d'identification de modulateurs de delta-like 4
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2019139980A8 (fr) Procédés de mesure d'un analyte et/ou d'une protéine dans des échantillons biologiques
WO2009020596A3 (fr) Liquide céphalorachidien embryonnaire (e-lcr), protéines issues du e-lcr et procédés et compositions associés
WO2008094945A3 (fr) Composes et procedes pour moduler l'expression des proteines
EA200701528A1 (ru) Новые нутрицевтические композиции
WO2008157459A3 (fr) Procédés et systèmes pour identifier des éléments de voie moléculaire
WO2007044083A3 (fr) Polypeptides d'interferon-alpha mis au point genetiquement
WO2007081878A8 (fr) Voies d'indoléamine 2,3-dioxygénase dans la production de lymphocytes t régulateurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867433

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867433

Country of ref document: EP

Kind code of ref document: A2